Literature DB >> 3967188

Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma.

J Radl, J W Croese, C Zurcher, M H van den Enden-Vieveen, R J Brondijk, M Kazil, J J Haaijman, P H Reitsma, O L Bijvoet.   

Abstract

The effects of the treatment of multiple myeloma (MM) with APD-bisphosphonate on bone destruction, the dissemination pattern of the MM, and toxicity for normal and malignant cells were investigated in an animal model, the 5T2 MM. This mouse MM very closely resembles the human disease, including the typical bone lesions. It was demonstrated by radiography, microradiography, and histologic investigation that the treatment of the 5T2 MM with APD-bisphosphonate protected the mice against a loss of bone to a significant extent. It seemed that the treatment with APD not only diminished the bone destruction by the MM but also led to the formation of new bone in already-affected bone tissue. The growth pattern of the MM was not substantially influenced by the treatment, even though there was an indication that APD exerts some cytotoxic effect on the MM cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3967188     DOI: 10.1002/1097-0142(19850301)55:5<1030::aid-cncr2820550518>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

Review 1.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

2.  Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.

Authors:  R Bataille; D Chappard; C Marcelli; P Dessauw; P Baldet; J Sany; C Alexandre
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

3.  Animal model of human disease. Multiple myeloma.

Authors:  J Radl; J W Croese; C Zurcher; M H Van den Enden-Vieveen; A M de Leeuw
Journal:  Am J Pathol       Date:  1988-09       Impact factor: 4.307

4.  Anticancer activity of bisphosphonic acids in methylnitrosourea-induced mammary carcinoma of the rat--benefit of combining bisphosphonates with cytostatic agents.

Authors:  F Wingen; B L Pool; P Klein; T Klenner; D Schmähl
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

Review 5.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

6.  Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)amino]phenyl]-1-hydroxybutane-1 1-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma.

Authors:  F Wingen; H Sterz; H Blum; H Möller; W Pittermann; B L Pool; H J Sinn; H Spring; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

7.  The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats.

Authors:  M Yamamoto; A Markatos; J G Seedor; P Masarachia; M Gentile; G A Rodan; R Balena
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

8.  Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat.

Authors:  F Wingen; T Eichmann; C Manegold; B Krempien
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

9.  The influence of genetic factors associated with the immunoglobulin heavy chain locus on the development of benign monoclonal gammapathy in ageing IgH-congenic mice.

Authors:  T W van den Akker; E de Glopper-van der Veer; J Radl; R Benner
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

10.  Idiopathic paraproteinaemia V. Expression of Igh1 and Igh5 allotypes within the homogeneous immunoglobulins of ageing (C57BL/LiARij X CBA/BrARij)F1 mouse.

Authors:  J Radl; M H Vieveen; T W van den Akker; R Benner; J J Haaijman; C Zurcher
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.